Teva Pharmaceutical Industries Limited balance sheet
At the end of its fiscal year on Dec 31, 2025, Teva Pharmaceutical Industries Limited reported total assets of $40.75B and shareholders' equity of $7.91B. That works out to liabilities equal to 81% of assets, a current ratio of 1.04 (current assets ÷ current liabilities).
Balance sheet at each fiscal year end
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $93.06B | $70.61B | $60.68B | $57.47B | $50.64B | $47.67B | $44.01B | $43.48B | $39.33B | $40.75B |
| Current assets | $17.23B | $15.38B | $13.79B | $13.46B | $13.01B | $12.57B | $12.05B | $12.48B | $12.55B | $13.95B |
| Cash & equivalents | $988.00M | $963.00M | $1.78B | $1.98B | $2.18B | $2.17B | $2.80B | $3.23B | $3.30B | $3.56B |
| Total liabilities | $58.06B | $51.87B | $44.89B | $42.41B | $39.58B | $36.42B | $35.41B | $35.35B | $33.61B | $32.83B |
| Current liabilities | $18.49B | $17.92B | $14.32B | $13.67B | $13.16B | $11.03B | $11.47B | $12.25B | $12.80B | $13.46B |
| Long-term debt | $32.52B | $28.83B | — | — | — | — | — | — | — | — |
| Shareholders' equity | $33.34B | $17.36B | $14.71B | $13.97B | $10.03B | $10.28B | $7.80B | $7.51B | $5.37B | $7.91B |
| Reported in | 10-K 2018 | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 |
Balance-sheet figures are point-in-time values on the last day of each fiscal year. Some companies (for example banks and insurers) do not present current assets and liabilities; those cells show —.
Source: SEC EDGAR XBRL company facts for CIK 818686 (raw data). Most recent filing in this dataset: 10-Q filed Nov 3, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.